Gilead Sciences, Inc. vs Uranium Energy Corp — how do they compare? Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B), while Uranium Energy Corp trades at $11.59 (market cap $5.67B). The key difference: Gilead Sciences, Inc. is far larger — about 29.7× Uranium Energy Corp's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| GILD | UEC | |
|---|---|---|
Market Cap | $168.35B | $5.67B |
Sector | Health | Energy |
52-Week High | $155.80 | $20.14 |
52-Week Low | $110.56 | $9.04 |
Enterprise Value | $191.42B | $5.18B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →